Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 32
- +2 vs. Q3 2023
- Portfolio value
- $1.14B
- +$289.0M (+33.8%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 4,747,373 | $130.6M | 11.4% | +319,301+7.2% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,167,793 | $99.8M | 8.7% | +322,793+17.5% | Added | History |
| NUVLNuvalent, Inc. | COM | 1,331,037 | $98.0M | 8.6% | +502,259+60.6% | Added | History |
| VERAVera Therapeutics, Inc. | CL A | 5,450,000 | $83.8M | 7.3% | 00.0% | Unchanged | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 1,550,000 | $71.3M | 6.2% | −525,000−25.3% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 1,100,000 | $69.1M | 6.0% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 1,900,000 | $43.1M | 3.8% | −625,753−24.8% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 1,000,000 | $42.1M | 3.7% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,924,074 | $41.9M | 3.7% | −275,926−12.5% | Reduced | History |
| ARVNArvinas, Inc. | COM | 1,000,000 | $41.2M | 3.6% | +1,000,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,884,084 | $40.5M | 3.5% | +1,767,760+1,519.7% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 2,901,816 | $40.2M | 3.5% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 5,566,026 | $32.7M | 2.9% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,610,000 | $30.7M | 2.7% | +285,000+21.5% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 700,000 | $28.2M | 2.5% | −187,500−21.1% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 701,967 | $27.8M | 2.4% | −4,698−0.7% | Reduced | History |
| CELCCelcuity Inc. | COM | 1,754,704 | $25.6M | 2.2% | +60,563+3.6% | Added | History |
| RYZBRayzeBio, Inc. | COM | 383,638 | $23.9M | 2.1% | +94,727+32.8% | Added | History |
| PHVSPharvaris N.V. | COM | 800,000 | $22.4M | 2.0% | +800,000 | New | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 3,800,000 | $21.5M | 1.9% | +3,800,000 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,895,003 | $20.3M | 1.8% | +1,895,003 | New | History |
| NKTXNkarta, Inc. | COM | 2,730,000 | $18.0M | 1.6% | +2,730,000 | New | History |
| KURAKura Oncology, Inc. | COM | 1,248,062 | $17.9M | 1.6% | −151,938−10.9% | Reduced | History |
| HARPHarpoon Therapeutics, Inc. | COM NEW | 1,500,000 | $17.1M | 1.5% | +1,500,000 | New | History |
| AKROAkero Therapeutics, Inc. | COM | 565,000 | $13.2M | 1.2% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 900,000 | $12.0M | 1.0% | +900,000 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $8.10M | 0.7% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 706,706 | $7.75M | 0.7% | −993,294−58.4% | Reduced | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 10,000,000 | $7.53M | 0.7% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 250,000 | $6.99M | 0.6% | 00.0% | Unchanged | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 1,831,746 | $1.26M | 0.1% | +1,831,746 | New | History |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 92,687 | $88.3K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q3 2023 (6)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 3,518,556 | $40.5M | 4.7% | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 775,000 | $20.9M | 2.4% | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 500,000 | $14.9M | 1.7% | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 957,509 | $13.9M | 1.6% | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 739,661 | $9.08M | 1.1% | History |
| MRSNMersana Therapeutics, Inc. | COM | 2,244,378 | $2.85M | 0.3% | History |